Recently, a delegation led by Mr. Peter Guenter, Member of the Executive Board and Chief Executive Officer of Healthcare at Merck Group, visited Abbisko's Shanghai R&D Center. 

Dr. Yaochang Xu, Founder and CEO of Abbisko, conveyed confidence in the partnership with Merck, emphasizing Merck's enduring industry leadership, exceptional innovation, top-tier products, and outstanding services. Abbisko anticipates strengthening mutual trust with Merck, exploring additional potential for collaboration between the two entities.

Mr. Peter Guenter stated that Abbisko is a leading Chinese biotech company, and expressed optimism for the further advancement of the global Phase III clinical trial of Pimicotinib this year. 

Dr. Jing Ji, CMO of Abbisko, and Dr. Zhui Chen, Co-founder, and CSO, shared progresses in the development of Pimicotinib since the parties entered into the license agreement and shared highlights of Abbisko’s pipeline. 

The Merck delegation was impressed by Abbisko's robust research capabilities and rigorous and pragmatic research philosophy.

The meeting was attended by key representatives, including Dr. Danny Bar-Zohar, Global Head of R&D and Chief Medical Officer,Hong Chow, Head of China and International Healthcare,Dr. Matthias Muellenbeck, Head of Business Development, Vivian Zhang, Managing Director and General Manager, Healthcare China , along with the management team of Abbisko.